Skip to content
← All treatment topics

TREATMENT READING

Childhood Pheochromocytoma and Paraganglioma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 9, 2024. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Pheochromocytoma and Paraganglioma Treatment.

Sources: Pheochromocytoma and Paraganglioma Treatment

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Childhood Pheochromocytoma and Paraganglioma

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 9, 2024. Captured 2026-09-09.

Treatment options for childhood paraganglioma and pheochromocytoma include the following:

Surgery.

Chemotherapy for patients with metastatic disease.

High-dose iodine I 131-labeled metaiodobenzylguanidine (131I-MIBG).

Lutetium Lu 177-DOTATATE and Yttrium Y 90-DOTATOC.[1]

Sources: 1

Tyrosine kinase inhibitor therapy (sunitinib and cabozantinib).[1]

Sources: 1

mTOR inhibitors.[1]

Sources: 1

Immunotherapy.[1]

Sources: 1

Treatment of paraganglioma and pheochromocytoma is surgical. For secreting tumors, alpha- and beta-adrenergic blockade must be optimized before surgery. A single-institution study reviewed the experience of laparoscopic partial adrenalectomy for bilateral pheochromocytoma in patients with von Hippel-Lindau disease.[2] In eight patients, all 16 adrenalectomies were performed laparoscopically. Fourteen of the procedures were partial adrenalectomies, and two patients required a contralateral total adrenalectomy because of tumor size and diffuse multinodularity. Two patients had new ipsilateral tumors identified after a median follow-up of 5 years (range, 4–6 years), with one patient who underwent repeat partial adrenalectomy. There were no deaths during the study period.

Sources: 2

For patients with metastatic disease, responses have been documented to some chemotherapeutic regimens such as gemcitabine and docetaxel or different combinations of vincristine, cyclophosphamide, doxorubicin, and dacarbazine.[3-5] Chemotherapy may help alleviate symptoms and facilitate surgery, although its impact on overall survival is less clear.

Sources: 3 · 5

Responses have also been obtained with high-dose 131I-MIBG and sunitinib.[6,7]

Sources: 6 · 7

Specific consensus guidelines for the diagnosis and management of pheochromocytoma and paraganglioma in patients with germline SDHB and SDHD pathogenic variants have been published.[8,9]

Sources: 8 · 9

Health professional

Treatment Options Under Clinical Evaluation for Childhood Pheochromocytoma and Paraganglioma

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 9, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following are examples of national and/or institutional clinical trials that are currently being conducted:

NCT04924075 (Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma and Paraganglioma or Pancreatic Neuroendocrine Tumor): This study will evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma or paraganglioma or pancreatic neuroendocrine tumor. The primary goal is to evaluate the objective response rate of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 by blinded independent central review.

Sources: NCT04924075

NCT04394858 (Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy [Temozolomide] for Advanced Neuroendocrine Cancer): This phase II trial will study the effectiveness of the addition of olaparib to temozolomide (the usual treatment) in treating patients aged 18 years and older with metastatic or unresectable pheochromocytomas or paragangliomas.

Sources: NCT04394858

For patients · General Information About Childhood Pheochromocytoma and Paraganglioma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Prognosis and treatment options depend on the following:

Sources: Prognosis

Whether the cancer has just been diagnosed or has recurred (come back).

Sources: recurred

For patients

Treatment Option Overview

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

There are different types of treatment for children with pheochromocytoma or paraganglioma.

Children with pheochromocytoma or paraganglioma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.

Four types of standard treatment are used:

Four types of standard treatment are used:

Surgery

Chemotherapy

High-dose 131I-MIBG therapy

Targeted therapy

New types of treatment are being tested in clinical trials.

Treatment of pheochromocytoma and paraganglioma may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for children with pheochromocytoma or paraganglioma.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.

Sources: standard · clinical trials · research study

Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.

For patients · Treatment Option Overview

Children with pheochromocytoma or paraganglioma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health professionals who are experts in treating children with cancer and who specialize in certain areas of medicine. This may include the following specialists and others:

Sources: pediatric oncologist · cancer · pediatric · medicine · specialists

Pediatrician.

Sources: Pediatrician

Pediatric surgeon.

Sources: Pediatric surgeon

Pathologist.

Sources: Pathologist

Pediatric endocrinologist.

Sources: endocrinologist

Pediatric nurse specialist.

Sources: Pediatric nurse specialist

Social worker.

Sources: Social worker

Rehabilitation specialist.

Sources: Rehabilitation specialist

Psychologist.

Sources: Psychologist

Child-life specialist.

Sources: Child-life specialist

For patients · Treatment Option Overview

Four types of standard treatment are used:

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

For patients · Treatment Option Overview / Four types of standard treatment are used:

Surgery

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Surgery to remove the tumor is the main treatment for pheochromocytoma and paraganglioma. For several days before surgery, your child may need to take blood pressure medicine to lower the risk of complications during and after surgery.

Sources: Surgery · tumor · pheochromocytoma · paraganglioma · blood pressure · complications

For patients · Treatment Option Overview / Four types of standard treatment are used:

Chemotherapy

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: Chemotherapy · drugs · cells · injected · vein · systemic chemotherapy

For patients · Treatment Option Overview / Four types of standard treatment are used:

High-dose 131I-MIBG therapy

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

131I-MIBG therapy is a treatment with high-dose radioactive iodine. The radioactive iodine is given through an intravenous (IV) line and enters the bloodstream which carries radiation directly to tumor cells. Radioactive iodine collects in pheochromocytoma and paraganglioma cells and kills them with the radiation that is given off.

Sources: 131I-MIBG · therapy · dose · radioactive iodine · intravenous · radiation

For patients · Treatment Option Overview / Four types of standard treatment are used:

Targeted therapy

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.

Sources: Targeted therapy · radiation therapy

Angiogenesis inhibitor drugs prevent the growth of new blood vessels needed for tumors to grow. Sunitinib is an angiogenesis inhibitor used to treat pheochromocytoma and paraganglioma.

Sources: Angiogenesis inhibitor · prevent · blood vessels · Sunitinib

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: clinical trials · NCI website

For patients · Treatment Option Overview

Treatment of pheochromocytoma and paraganglioma may cause side effects.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).

For patients with pheochromocytoma or paraganglioma that causes symptoms, catecholamine levels in the blood and urine will be checked on a regular basis. Catecholamine levels that are higher than normal can be a sign that the cancer has come back. Talk to your child’s doctor about which tests should be done and how often.

Sources: symptoms · catecholamine · blood · urine · sign

Patients with pheochromocytoma or paraganglioma need lifelong follow-up.

Sources: follow-up

For patients

Treatment of Childhood Pheochromocytoma and Paraganglioma

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed pheochromocytoma and paraganglioma in children may include the following:

Sources: diagnosed · pheochromocytoma · paraganglioma

Surgery to completely remove the tumor.

Sources: Surgery · tumor

Combination chemotherapy, high-dose 131I-MIBG therapy, or targeted therapy for tumors that have spread to other parts of the body.

Sources: Combination chemotherapy · dose · 131I-MIBG · therapy · targeted therapy

Before surgery, drug therapy with alpha-blockers to control blood pressure and beta-blockers to control heart rate are given. If both adrenal glands are removed, life-long hormone therapy to replace hormones made by the adrenal glands is needed after surgery.

Sources: drug therapy · alpha-blockers · blood pressure · beta-blockers · heart rate · adrenal glands · hormone therapy · hormones

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Childhood Pheochromocytoma and Paraganglioma

Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 21, 2022. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of recurrent pheochromocytoma and paraganglioma may include the following:

Sources: recurrent · pheochromocytoma · paraganglioma

A clinical trial that checks a sample of the patient's tumor for certain gene changes. The type of targeted therapy that will be given to the patient depends on the type of gene change.

Sources: clinical trial · tumor · gene · targeted therapy

A clinical trial of 131I-MIBG therapy.

Sources: 131I-MIBG · therapy

A clinical trial of a new chemotherapy drug (guadecitabine).

Sources: chemotherapy · drug · guadecitabine

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

NCT04394858 · ACTIVE NOT RECRUITING · phase2

Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Stage III Adrenal Gland Pheochromocytoma...

ClinicalTrials.gov record

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075 · RECRUITING · phase2

Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers

ClinicalTrials.gov record